Curated News
By: NewsRamp Editorial Staff
October 09, 2025
Soligenix Expands European Advisory Board for CTCL Treatment
TLDR
- Soligenix's expansion of its European Medical Advisory Board positions HyBryte to become the new standard of care for CTCL, creating a competitive advantage in the European market.
- HyBryte is a first-in-class photodynamic therapy using synthetic hypericin as a photosensitizer, currently undergoing confirmatory phase 3 study FLASH2 for CTCL treatment safety and efficacy.
- Soligenix's HyBryte development addresses the substantial unmet medical need for CTCL patients in Europe, potentially improving treatment options for millions suffering from this rare lymphoma.
- HyBryte represents a novel photodynamic therapy approach using synthetic hypericin to treat cutaneous T-cell lymphoma, a rare but serious form of non-Hodgkin lymphoma.
Impact - Why it Matters
This development matters because Cutaneous T-cell lymphoma represents a significant unmet medical need with limited treatment options, particularly for early-stage patients. The advancement of HyBryte could establish a new standard of care for a rare but serious condition affecting millions globally. For patients suffering from CTCL, this represents potential access to a first-in-class therapy that may offer better outcomes and improved quality of life. The European expansion also signals growing international recognition of this innovative treatment approach, potentially accelerating regulatory approvals and patient access across multiple markets. In the broader context of rare disease treatment, successful development of HyBryte could demonstrate the viability of photodynamic therapies for other challenging medical conditions.
Summary
Soligenix (NASDAQ: SNGX), a biotechnology company focused on developing innovative treatments for rare diseases, has significantly expanded its European Medical Advisory Board to advance the development of HyBryte™, its groundbreaking treatment for Cutaneous T-cell lymphoma (CTCL). This strategic expansion underscores the company's commitment to delivering novel therapeutic options to European patients suffering from this rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. The enhanced advisory board will provide crucial clinical and strategic guidance as Soligenix progresses its confirmatory phase 3 study, known as FLASH2, which is evaluating the safety and efficacy of HyBryte for CTCL patients who currently face limited treatment options.
HyBryte represents a first-in-class photodynamic therapy that utilizes synthetic hypericin as a photosensitizer, positioning it as a potential new standard of care for early-stage CTCL patients. The company's efforts through its expanded European Medical Advisory Board aim to navigate the complex regulatory and clinical landscape in Europe, where CTCL affects an estimated 2.9 to 3.9 cases per million people annually according to recent data. This expansion reflects Soligenix's strategic approach to ensuring the successful execution of the FLASH2 study and ultimately bringing this innovative treatment to patients who desperately need better options. The company's work through its Dynamic Brand Portfolio and strategic communications platforms demonstrates its comprehensive approach to advancing medical solutions for underserved patient populations.
The development of HyBryte addresses a substantial unmet medical need in the CTCL treatment landscape, particularly for patients in early stages of the disease who often have limited therapeutic choices. Soligenix's commitment to expanding its European Medical Advisory Board and advancing the FLASH2 study represents a significant step forward in potentially establishing HyBryte as a transformative treatment option. As the company continues to leverage its specialized communications platform and strategic partnerships, this development could have far-reaching implications for CTCL patients across Europe and beyond, offering hope for improved outcomes and quality of life for those affected by this challenging condition.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Expands European Advisory Board for CTCL Treatment
